



Medi-Cal Rx

Medi-Cal Rx Monthly Bulletin

September 1, 2026

Medi-Cal Rx has implemented or scheduled the following updates. Stay up to date with all that is happening at Medi-Cal Rx by visiting the [Bulletins & News](#) page and signing up for the [Medi-Cal Rx Subscription Service](#) to receive notification of future publications.

1. [Updates to the Medi-Cal Rx Contract Drugs List](#)
2. [Diabetic Supplies Update: Updates to the List of Contracted Continuous Glucose Monitoring \(CGM\) Systems, Effective October 1, 2026](#)
3. [Updates to the Medi-Cal Rx Provider Manual](#)
4. [Update: Basaglar® \(Insulin Glargine\) Removal from the Medi-Cal Rx Contract Drugs List Postponed Until November 1, 2026](#)
5. [Updates to the Medi-Cal Rx NCPDP Payer Specification Sheet](#)
6. [Updates to the Now Active: MMRV Vaccine Reimbursement for Children Younger Than 4 Years of Age](#)
7. [Maximum Allowable Ingredient Cost 30-Day Pharmacy Provider Notice](#)
8. [Updates to the Reminder: Establishing Medical Necessity](#)
9. [Updates to the Prior Authorization Submission Reminders](#)
10. [Updates to the Medi-Cal Reimbursement of Vaccines for VFC and Non-VFC Enrolled Pharmacy Providers – Frequently Asked Questions \(FAQs\)](#)
11. [Updates to the Medi-Cal Rx Portal Prior Authorization Request Job Aid](#)
12. [Updates to the Medi-Cal Rx Enteral Nutrition Prior Authorization Request \(DHCS 6505\) Form](#)
13. [Updates to the Medi-Cal Rx Prior Authorization Request \(DHCS 6560\) Form](#)

1. Updates to the Medi-Cal Rx Contract Drugs List

The following updates have been made to the [Medi-Cal Rx Contract Drugs List](#) (CDL).

Drug Name	Description
Amlodipine/Valsartan/ Hydrochlorothiazide	Effective November 1, 2026: Removed from the CDL.
Atenolol/Chlorthalidone	Added to the CDL.
Candesartan Cilexetil/ Hydrochlorothiazide	Added to the CDL.
Dofetilide	Added to the CDL.
Dronedaron HCL	Added to the CDL with labeler restriction (LR).
Isatuximab-Irfc	Additional strength (1,400 mg/10 ml) added to the CDL with LR.
Ivabradine HCL	Added to the CDL.
Mechlorethamine HCL	LR added.
Olmesartan Medoxomil/ Amlodipine/Hydrochlorothiazide	Added to the CDL.
Propafenone HCL	Additional formulation (extended-release capsules) added to the CDL.
Roflumilast	LR added to 0.15%, 0.3% cream and 0.5 foam. Additional strength (0.05%) added to the CDL with LR and quantity limit (QL).
Tislelizumab-Jsgr	Additional strength (150 mg/15 mL) added to the CDL with LR.

2. Diabetic Supplies Update: Updates to the List of Contracted Continuous Glucose Monitoring (CGM) Systems, Effective October 1, 2026

The [List of Contracted Continuous Glucose Monitoring \(CGM\) Systems](#) has been updated on the [Medi-Cal Rx Web Portal](#). The effective date of the change is October 1, 2026.

The following product will be added to the *List* as a covered pharmacy benefit:

Product Label Name	Medi-Cal 11 Digit Billing Number (NDC)	MAC/MAPC Price Per Each
Dexcom® G7 15-Day Sensor, 1 each	08627007901	188.2900

Note: Prior authorization (PA) is required for coverage, and quantity and frequency limits apply.

Contractors have guaranteed that Medi-Cal Rx providers may purchase, upon request, for dispensing to eligible Medi-Cal members, covered products at or below the Maximum Acquisition Cost (MAC). Providers can locate MAC price suppliers by calling manufacturer phone numbers referenced in the *Lists* on the [Contract Drugs & Covered Products Lists](#) page on the [Medi-Cal Rx Web Portal](#).

Note: Product addition or inclusion on the *List* does not guarantee supply or individual-specific coverage.

Medi-Cal members denied coverage of a requested Medi-Cal Rx product have the right to a State Hearing. A State Hearing may be requested by contacting the California Department of Social Services, State Hearings Division, at the following address:

[State Hearings](#)

P.O. Box 944243, MS 21-37
Sacramento, CA 94244-2430

Toll Free: 1-800-743-8525 or 1-855-795-0634
Fax: 1-833-281-0905

Medi-Cal members have the right and are encouraged to consult their primary care provider or prescriber to determine if an appropriate substitute product is available and covered by Medi-Cal Rx.

3. Updates to the Medi-Cal Rx Provider Manual

The following updates/additions have been made to the [Medi-Cal Rx Provider Manual](#).

Section	Update Description
<i>Section 4.6.11 – Non-Standard Benefits/Items Not Covered</i>	Updated section title and added information about non-standard benefits, including requirements for potential reimbursement.
<i>Section 8.2.1 – Long Term Care Claims Processing</i>	Added a reference to <i>Section 4.6.11</i>.
<i>Section 11.2 – Limitations on Coverage of Certain Drugs or Classes of Drugs</i>	Added a reference to <i>Section 4.6.11</i>.
<i>Section 14.1 – PA Request Overview</i>	Added a reference to <i>Section 4.6.11</i>.

Section	Update Description
<i>Section 14.8 – Establishing Medical Necessity for PA Requests</i>	Updated the list of required information when submitting PA requests to establish medical necessity.
<i>Appendix G – OHC Carrier Information</i>	Added carriers to the list of Other Health Coverage (OHC) carriers.

4. Update: Basaglar® (Insulin Glargine) Removal from the Medi-Cal Rx Contract Drugs List Postponed Until November 1, 2026

What Prescribers Need to Know

Medi-Cal Rx has postponed the removal of Basaglar® (insulin glargine), NDC labeler code 00002, from the [CDL](#) until November 1, 2026. This postponement ensures members will continue to have access despite the unanticipated supply chain concerns. Claims submitted for this drug without an approved PA, with a date of service (DOS) on or after November 1, 2026, will deny with **Reject Code 606 – Brand Drug/Specific Labeler Code Required**. A PA request demonstrating medical justification for use over a CDL-listed product will need to be submitted for coverage consideration.

What Prescribers Need to Do

- Prescribers should consider alternate covered therapies that are listed on the CDL (such as Lantus® [insulin glargine] or insulin glargine-yfqn), if clinically appropriate. Refer to the [Medi-Cal Rx Approved NDC List](#) on the [Medi-Cal Rx Web Portal](#).
- If a change in therapy is not appropriate, beginning November 1, 2026, submit a PA request via one of the five approved PA request submission methods demonstrating medical justification:
 - [CoverMyMeds®](#)
 - [Medi-Cal Rx Secured Provider Portal](#)
 - NCPDP P4 Transaction
 - Fax
 - U.S. Mail

5. Updates to the Medi-Cal Rx NCPDP Payer Specification Sheet

Medi-Cal Rx published updates to the [Medi-Cal Rx NCPDP Payer Specification Sheet](#) on August 21, 2026. To access the document, visit the [Medi-Cal Rx Provider Portal](#) and select the **Billing Tips & Payer Sheet** tab on the [Forms & Information](#) page.

6. Updates to the Now Active: MMRV Vaccine Reimbursement for Children Younger Than 4 Years of Age

Medi-Cal Rx published updates to the [Now Active: MMRV Vaccine Reimbursement for Children Younger Than 4 Years of Age](#) alert on August 21, 2026. To access the document, visit the [Bulletins & News](#) page on the [Medi-Cal Rx Provider Portal](#).

7. Maximum Allowable Ingredient Cost 30-Day Pharmacy Provider Notice

The Department of Health Care Services (DHCS) has contracted with Prime Therapeutics State Government Solutions LLC (Prime), who contracts with Mercer Government Human Services Consulting (Mercer), part of Mercer Health and Benefits, LLC, to establish and maintain a Maximum Allowable Ingredient Cost (MAIC) program for generic pharmaceutical drugs.

Rates will be effective October 1, 2026, and will be posted to the Mercer Medi-Cal Rx website no later than September 1, 2026.

- Refer to the [Mercer Medi-Cal Rx website](#) for MAIC rate lists, MAIC program information, Frequently Asked Questions (FAQs), and contact information.
- To request a review of a MAIC rate for a specific drug, submit a request using the [Medi-Cal Rx Maximum Allowable Ingredient Cost Price Research Request \(DHCS 6540\)](#) form found on the [Mercer Medi-Cal Rx website](#) and the [Forms & Information](#) page on the [Medi-Cal Rx Provider Portal](#).

Note: All required fields on the form must be completed. Providers will be contacted for supporting documentation or other information, as necessary.

The primary method for pharmacy provider notifications for the MAIC and Annual Attestation Survey is via email and/or fax. It is important and recommended that pharmacy providers maintain accurate and consistent contact information across all organizations involved in pharmacy administration, including but not limited to, NCPDP and Medi-Cal.

8. Updates to the Reminder: Establishing Medical Necessity

Medi-Cal Rx published updates to the [Reminder: Establishing Medical Necessity](#) alert on August 31, 2026. To access the document, visit the [Bulletins & News](#) page on the [Medi-Cal Rx Provider Portal](#).

9. Updates to the Prior Authorization Submission Reminders

Medi-Cal Rx published updates to the [Prior Authorization Submission Reminders](#) document on August 31, 2026. To access the document, visit the [Bulletins & News](#) page on the [Medi-Cal Rx Provider Portal](#).

10. Updates to the Medi-Cal Reimbursement of Vaccines for VFC and Non-VFC Enrolled Pharmacy Providers – Frequently Asked Questions (FAQs)

Medi-Cal Rx published updates to the [Medi-Cal Reimbursement of Vaccines for VFC and Non-VFC Enrolled Pharmacy Providers – Frequently Asked Questions \(FAQs\)](#) on August 21, 2026. To access the document, visit the [FAQ](#) page on the [Medi-Cal Rx Web Portal](#).

11. Updates to the Medi-Cal Rx Portal Prior Authorization Request Job Aid

Medi-Cal Rx published updates to the [Medi-Cal Rx Portal Prior Authorization Request Job Aid](#) on August 31, 2026. To access the document, visit the [Medi-Cal Rx Provider Portal](#) and select the **Reference Materials** tab on the [Forms & Information](#) page.

12. Updates to the Medi-Cal Rx Enteral Nutrition Prior Authorization Request (DHCS 6505) Form

Medi-Cal Rx published updates to the [Medi-Cal Rx Enteral Nutrition Prior Authorization Request \(DHCS 6505\)](#) form on August 31, 2026. To access the document, visit the [Medi-Cal Rx Provider Portal](#) and select the **Reference Materials** tab on the [Forms & Information](#) page.

13. Updates to the Medi-Cal Rx Prior Authorization Request (DHCS 6560) Form

Medi-Cal Rx published updates to the [Medi-Cal Rx Prior Authorization Request \(DHCS 6560\)](#) form on August 31, 2026. To access the document, visit the [Medi-Cal Rx Provider Portal](#) and select the **Reference Materials** tab on the [Forms & Information](#) page.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.